<DOC>
	<DOC>NCT01032902</DOC>
	<brief_summary>This study has been designed to evaluate the performance of the Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 rapid test. The device is intended to qualitatively detect the presence of antibodies against HIV-1/2 in oral fluid, whole blood (capillary and venous), serum or plasma. This study will assess the DPP® HIV 1/2 Screen assay's ability to detect HIV-1.</brief_summary>
	<brief_title>Evaluation of the Performance of Chembio Diagnostics Systems, Inc. DPP® HIV 1/2 Rapid Test</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Must be at least 2 years of age (no upper age limit). Must be willing and able to receive posttest counseling, if applicable. Must sign (and be given) a copy of the written Informed Consent form and or Assent form (if applicable). Must be able to sustain fingersticks and venipuncture from the arm or hand only. Am in a life threatening condition at the time of enrollment Have a suppressed immune systems (i.e. transplant patients, individuals diagnosed with nonHIV immunosuppressive illness, etc.). Have participated or are participating in a clinical trial for an HIV vaccine. Have previously participated in this clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Human immunodeficiency virus</keyword>
	<keyword>Rapid Test</keyword>
	<keyword>HIV</keyword>
	<keyword>HIV Seronegativity</keyword>
</DOC>